CA2231332A1 - Systeme d'apport bacterien - Google Patents

Systeme d'apport bacterien

Info

Publication number
CA2231332A1
CA2231332A1 CA002231332A CA2231332A CA2231332A1 CA 2231332 A1 CA2231332 A1 CA 2231332A1 CA 002231332 A CA002231332 A CA 002231332A CA 2231332 A CA2231332 A CA 2231332A CA 2231332 A1 CA2231332 A1 CA 2231332A1
Authority
CA
Canada
Prior art keywords
delivery system
bacterial delivery
bacterial
shigella
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002231332A
Other languages
English (en)
Other versions
CA2231332C (fr
Inventor
Arthur A. Branstrom
Donata R. Sizemore
Jerald C. Sadoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Army
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/523,855 external-priority patent/US5824538A/en
Application filed by Individual filed Critical Individual
Publication of CA2231332A1 publication Critical patent/CA2231332A1/fr
Application granted granted Critical
Publication of CA2231332C publication Critical patent/CA2231332C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0283Shigella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002231332A 1995-09-06 1996-09-06 Systeme d'apport bacterien Expired - Fee Related CA2231332C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US331895P 1995-09-06 1995-09-06
US60/003,318 1995-09-06
US08/523,855 US5824538A (en) 1995-09-06 1995-09-06 Shigella vector for delivering DNA to a mammalian cell
US08/523,855 1995-09-06
US1803596P 1996-05-21 1996-05-21
US60/018,035 1996-05-21
PCT/US1996/014190 WO1997008955A1 (fr) 1995-09-06 1996-09-06 Systeme d'apport bacterien

Publications (2)

Publication Number Publication Date
CA2231332A1 true CA2231332A1 (fr) 1997-03-13
CA2231332C CA2231332C (fr) 2007-04-17

Family

ID=27357382

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002231332A Expired - Fee Related CA2231332C (fr) 1995-09-06 1996-09-06 Systeme d'apport bacterien

Country Status (6)

Country Link
EP (1) EP0881884A4 (fr)
JP (1) JP2000500734A (fr)
AU (1) AU731061B2 (fr)
CA (1) CA2231332C (fr)
IL (1) IL123569A (fr)
WO (1) WO1997008955A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734605T2 (de) 1997-04-18 2006-08-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
EP1012232B1 (fr) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Bacteries a virulence reduite modifiees genetiquement ciblees sur des tumeurs
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
CA2305785A1 (fr) * 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Procede d'introduction et d'expression d'arn dans des cellules animales
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
US6825028B1 (en) * 1998-12-11 2004-11-30 Christoph Von Eichel-Streiber Recombinant listeria
US6143551A (en) * 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
CU22661A1 (es) * 1997-12-30 2001-04-27 Cnic Ct Nac Investigaciones Nuevos candidatos vacunales de vibrio cholerae y método de obtención
US6596477B1 (en) 1998-09-28 2003-07-22 University Of Maryland Biotechnology Institute Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2001025397A2 (fr) * 1999-10-04 2001-04-12 Vion Pharmaceuticals, Inc. Compositions et methodes d'administration ciblees sur les tumeurs de molecules effectrices
US8053568B2 (en) * 2004-11-30 2011-11-08 Aeras Global Tb Vaccine Foundation Bacterial packaging strains useful for generation and production of recombinant double-stranded RNA nucleocapsids and uses thereof
WO2006066048A2 (fr) * 2004-12-17 2006-06-22 Beth Israel Deaconess Medical Center Compositions de mise en veille de genes mediee par une bacterie et leurs procedes d'utilisation
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
AR242989A1 (es) * 1988-07-15 1993-06-30 Inst Pasteur I Nat De La Sante Metodo para modificar una cepa salvaje de una shigella entero-invasora para producir una cepa modificada apta para preparar una vacuna contra la cepa salvaje y cepa de shigella asi modificada.

Also Published As

Publication number Publication date
EP0881884A4 (fr) 2004-07-14
IL123569A (en) 2006-10-05
AU731061B2 (en) 2001-03-22
AU7105996A (en) 1997-03-27
WO1997008955A1 (fr) 1997-03-13
EP0881884A1 (fr) 1998-12-09
CA2231332C (fr) 2007-04-17
IL123569A0 (en) 1998-10-30
JP2000500734A (ja) 2000-01-25

Similar Documents

Publication Publication Date Title
CA2231332A1 (fr) Systeme d'apport bacterien
AU5887296A (en) Process for the transcriptionless amplification of nucleic aids
CA2190324A1 (fr) Methode et composition pour empecher la croissance de microorganismes, grace a l'utilisation d'acide peracetique et d'un biocide non oxydant
ATE219499T1 (de) Lipopeptid-derivate, verfahren zu ihrer herstellung und ihre verwendung
AU7508794A (en) Novel lipase, microorganism producing the lipase, process for producing the lipase, and use of the lipase
AU5450998A (en) Methods for controlling above-ground plant diseases using antibiotic-producing strains of (bacillus sp.)
CA2344166A1 (fr) Compositions de .beta.-glucanes et d'immunoglobulines specifiques
AU5001496A (en) Introduction of dna into bacillus strains by conjugation
WO1997005899A3 (fr) Nouveaux vaccins et nouvelles compositions pharmaceutiques utilisant des vesicules de membrane de micro-organismes et leurs procedes d'elaboration
AU694292B2 (en) Process for deactivating or destroying microorganisms
WO2001040280A3 (fr) Composition et procede destines a traiter une infection microbienne
MD960242A (en) Microorganisms for biological control of plants diseases
AU2354095A (en) Process for inhibiting the growth of a culture of lactic acid bacteria, and optionally lysing the bacterial cells, and uses of the resulting lysed culture
CA2148563A1 (fr) Proteine p5 d'haemophilus influenzae non typable, purifiee, utilisee comme vaccin contre une souche d'haemophilus influenzae non typable
AU8113694A (en) Water treatment system comprising water-soluble glass
CA2029201A1 (fr) Procede pour la purification d'antigenes b pertussis
EP1258486A3 (fr) Procédé de préparation de 2,2-difluorokétène silyl o,s-acetales et des O,S esters de l'acide alpha,alpha-difluoro-beta-silyloxy-1,3-dioxolane-4-propanoique
EP0757098A3 (fr) Maltose phosphorylase résistante à la chaleur, procédé pour sa préparahon, bactéries uliliseés pour sa préparation et méthodes d'utilisation de cette enzyme
DE68913128D1 (de) Verfahren zur Herstellung von L-Alanin-Dehydrogenase und Mikroorganismusstamm des Genus Sporolactobacillus.
AU2548597A (en) Antibodies against avirulence/pathogenicity proteins of plant pathogens
WO2001047962A3 (fr) Micro-organismes attenues servant a traiter des infections
EP1574579A3 (fr) Protéines de membranes externes, leurs gènes, et leur utilisation
AU3046595A (en) Commercial scale concentrated preharvest tissue culture produced live T.gondii bradyzoite and products and processes
AU4950597A (en) Composition containing chitosan
AU4732396A (en) Novel lipase, process for producing the same, and microorganism producing the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed